A

t first glance, the landmark experiments using CRISPR to correct a mutation in human embryos represent a breakthrough, since they demonstrated three key things: that CRISPR can delete the gene it’s supposed to in a viable embryo, that it can make the change in a way that causes all of an embryo’s cells to have it (when some embryo cells but not others have their DNA changed it’s called mosaicism and would be a problem), and that CRISPR can do this with few if any unintended edits, or off-target effects.

But when STAT spoke to the lead scientist, reproductive biologist Shoukhrat Mitalipov of Oregon Health and Science University, two days before his study was published in Nature, he had a different view on his experiment.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X